New weight loss treatment in Mexico? Here's what we know

In the last three decades Obesity has doubled among people over 18 worldwide and overweight adults now affect 2.5 billion people , a growth that has worsened, especially in low- and middle-income countries, where there is a greater presence of foods rich in fat and sugar, as is the case of Mexico , which is now looking for a way out of this crisis .

According to the World Health Organization ( WHO ), obesity is a public health problem that annually causes the death of approximately three million people from diseases related to this condition, with cardiovascular diseases being the main cause.

America is the part of the world with the highest obesity rate, according to the WHO , since its rates, driven by unhealthy eating habits and lack of physical activity, have increased dramatically in recent decades, especially in countries such as the United States and Mexico.

READ ALSO: How to detect kidney failure in time? These are some signs Weight loss treatment in Mexico

In the face of this crisis, Novo Nordisk , a Danish company that has been researching obesity treatments for more than 25 years, announced that, Starting in April 2025, it will launch a weight loss treatment in Mexico , which will be based on semaglutide 2.4 mg, a drug from the GLP-1 analogues, the action of which helps to reduce hunger and increase the feeling of satiety.

According to Mike Vivas, senior medical director of Novo Nordisk Mexico , this "represents a significant advance in the treatment of obesity and is a clear demonstration of the company's commitment to people living with this disease in our country."

In addition to this, clinical research has shown that the drug allows an average weight reduction of 17.5%, and in some cases, up to 20% in 68 weeks , which is why the Federal Commission for the Protection against Sanitary Risks (Cofepris) approved its use for people with obesity, overweight and the presence of at least one comorbidity.

According to the specialist, Obesity is "a multifactorial disease that is not due to a single cause; it is not just about overeating and leading a sedentary lifestyle. It is the result of a combination of sociocultural, genetic, environmental, psychological and metabolic factors."

Therefore, the person should have professional support in order to, he added, "establish the appropriate approach to help them lose weight and improve their physical, mental and emotional health."

The drug is added to the alternatives available for the treatment of overweight and obesity in Mexico, whose impact will depend on medical adoption.

In addition to accompanying this medication with a healthy and balanced diet, as well as regular physical activity, Vivas reiterated that "it is crucial that the indication of any pharmacological treatment, including semaglutide 2.4 mg, is always performed and monitored by a physician ".

YOU MAY BE INTERESTED IN: Increase in kidney disease in Mexico is reported; preventive measures are required

AB